Skip to main content
Top

06-05-2024 | Nephrotic Syndrome | Original article

Prediction model for treatment response of primary membranous nephropathy with nephrotic syndrome

Authors: Min Li, Xiaoying Lai, Jun Liu, Yahuan Yu, Xianyi Li, Xuemei Liu

Published in: Clinical and Experimental Nephrology

Login to get access

Abstract

Objective

To investigate the predictors and establish a nomogram model for the prediction of the response to treatment in primary membranous nephropathy (PMN) with nephrotic syndrome (NS).

Methods

The clinical, laboratory, pathological and follow-up data of patients with biopsy-proven membranous nephropathy at the Affiliated Hospital of Qingdao University were collected. A total of 373 patients were randomly assigned into development group (n = 262) and validation group (n = 111). Logistic regression analysis was performed in the development group to determine the predictors of treatment response. A nomogram model was established based on the multivariate logistic regression analysis and validated in the validation group. The C-index and calibration plots were used for the evaluation of the discrimination and calibration performance, respectively.

Results

Serum albumin levels (OR = 1.151, 95% CI 1.078–1.229, P < 0.001) and glomerular C3 deposition (OR = 0.407, 95% CI 0.213–0.775, P = 0.004) were identified as independent predictive factors for treatment response in PMN with NS, then a nomogram was established combining the above indicators and treatment regimen. The C-indices of this model were 0.718 (95% CI 0.654–0.782) and 0.789 (95% CI 0.705–0.873) in the development and validation groups, respectively. The calibration plots showed that the predicted probabilities of the model were consistent with the actual probabilities (P > 0.05), which indicated favorable performance of this model in predicting the treatment response probability.

Conclusions

Serum albumin levels and glomerular C3 deposition were predictors for treatment response of PMN with NS. A novel nomogram model with good discrimination and calibration was constructed to predict treatment response probability at an early stage.
Literature
1.
6.
go back to reference Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986–98. https://doi.org/10.1016/j.kint.2020.10.014.CrossRefPubMed Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986–98. https://​doi.​org/​10.​1016/​j.​kint.​2020.​10.​014.CrossRefPubMed
8.
go back to reference Liu LS. 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(7):579–615.PubMed Liu LS. 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(7):579–615.PubMed
9.
go back to reference Endocrinology Branch of Chinese Medical Association. China expert consensus on the treatment of hyperuricemia and gout. Chin J Endocrinol Metab. 2013;11:913–20. Endocrinology Branch of Chinese Medical Association. China expert consensus on the treatment of hyperuricemia and gout. Chin J Endocrinol Metab. 2013;11:913–20.
27.
go back to reference Xie Z, Dong W, Li Z, Chen Y, Song L, Li R, et al. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: a retrospective cohort study. Nephrology (Carlton). 2020;25(3):219–29. https://doi.org/10.1111/nep.13691.CrossRefPubMed Xie Z, Dong W, Li Z, Chen Y, Song L, Li R, et al. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: a retrospective cohort study. Nephrology (Carlton). 2020;25(3):219–29. https://​doi.​org/​10.​1111/​nep.​13691.CrossRefPubMed
35.
go back to reference Alivernini S, Tolusso B, Gessi M, Gigante MR, Mannocci A, Petricca L, et al. Inclusion of synovial tissue-derived characteristics in a nomogram for the prediction of treatment response in treatment-naive rheumatoid arthritis patients. Arthritis Rheumatol (Hoboken, NJ). 2021;73(9):1601–13. https://doi.org/10.1002/art.41726.CrossRef Alivernini S, Tolusso B, Gessi M, Gigante MR, Mannocci A, Petricca L, et al. Inclusion of synovial tissue-derived characteristics in a nomogram for the prediction of treatment response in treatment-naive rheumatoid arthritis patients. Arthritis Rheumatol (Hoboken, NJ). 2021;73(9):1601–13. https://​doi.​org/​10.​1002/​art.​41726.CrossRef
Metadata
Title
Prediction model for treatment response of primary membranous nephropathy with nephrotic syndrome
Authors
Min Li
Xiaoying Lai
Jun Liu
Yahuan Yu
Xianyi Li
Xuemei Liu
Publication date
06-05-2024
Publisher
Springer Nature Singapore
Published in
Clinical and Experimental Nephrology
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-024-02470-1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.